Ionis Pharmaceuticals, Inc. (IONS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Insights - Ionis is positioned as a genetic medicines company focusing on RNA-targeted treatments for diseases with high unmet needs, indicating a strong commitment to innovation in the biotech sector [2] - The year 2026 is anticipated to be transformational for Ionis, building on the momentum established in 2025, which was marked by significant achievements [2] Company Performance - In 2025, Ionis launched its first two independent medicines, including the FDA-approved treatment for familial chylomicronemia syndrome (FCS), named Tryngolza, marking a significant milestone in the company's history [2] - The launch of Tryngolza was described as a spectacular success, achieving $108 million in total revenue for the year and exceeding all estimates, showcasing strong quarter-over-quarter growth [2]